COCP Stock Forecast: Cocrystal Pharma, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.93
−4.11% on the day

The median 12-month analyst price target for Cocrystal Pharma, Inc. is $8. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 48 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$18.7M
Ticker Nerd rank
48/ 100
Median analyst target
$8.00
Analysts covering
2
Revenue$105K
Operating income−$3.2M
Net income−$3.2M
Free cash flow−$2.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.1%
1M
−1.1%
YTD
−5.1%
1Y
+1.1%
From 52W high
−40.8%
From 52W low
+13.4%
$0.82
$1.57
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Cocrystal Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
48/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
89
Volatility
76
Value
57
Issuance
54
Momentum
50
Revisions
25
Quality
24
Growth
24

Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (24): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

COCP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COCP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26COCPHigh $10.00Median $8.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$6.00
Low
$8.00
Median
$10.00
High
Recent analyst actionsNewest first

Of the 18 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
20 June 2025HC Wainwright & Co.MaintainsBuy$7.00 → $6.00
22 Jan 2025HC Wainwright & Co.ReiteratesBuy—
22 Aug 2024HC Wainwright & Co.MaintainsBuy$10 → $7.00
14 May 2024HC Wainwright & Co.ReiteratesBuy—
4 Apr 2024HC Wainwright & Co.ReiteratesBuy—
20 Mar 2024HC Wainwright & Co.ReiteratesBuy—
3 Jan 2024HC Wainwright & Co.MaintainsBuy—
4 Dec 2023HC Wainwright & Co.ReiteratesBuy—
4 Oct 2023HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023HC Wainwright & Co.ReiteratesBuy—
11 Aug 2023HC Wainwright & Co.ReiteratesBuy—
2 June 2023HC Wainwright & Co.ReiteratesBuy—
24 May 2023HC Wainwright & Co.MaintainsBuy—
24 Jan 2023HC Wainwright & Co.MaintainsBuy—
7 Nov 2022HC Wainwright & Co.MaintainsBuy—
12 Nov 2020HC Wainwright & Co.MaintainsBuy$5.00 → $4.50
8 July 2020HC Wainwright & Co.InitiatesBuy—
16 June 2020Noble Capital MarketsInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for COCP.

Market Radar

This page is one stock. Monday covers all of them.

COCP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

COCP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Cocrystal Pharma, Inc. returned +1.1% against +6.9% for the S&P 500, dividends included.

COCP vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Jan 26Apr 26Jul 26Oct 26COCPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COCP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
41.7×

Cheaper than 5% of US stocks

Price / book
6.8×

Cheaper than 12% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−53.3%

Higher than 5% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−219.1%

Higher than 7% of US stocks

Return on assets
−83.6%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cocrystal Pharma, Inc. has a market value of $18.7M and an enterprise value of $15.1M.

  • Revenue in the twelve months to 30 June 2026: $330K.

  • Net income over the same four quarters: −$9.9M, a −3011.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$8.0M.

  • Shares outstanding: 13.8M.

  • Cocrystal Pharma, Inc. employs 10 people — $33K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

COCP and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
COCPCocrystal Pharma, Inc.$18.7M48
MRKRMarker Therapeutics, Inc.$18.2M76
KTTAPasithea Therapeutics Corp.$17.6M13
IGCIGC Pharma, Inc.$19.5M14
RNAZTransCode Therapeutics, Inc.$19.6M12
AARDAardvark Therapeutics, Inc.$20.1M15
LPCNLipocine, Inc.$16.4M39

Take a look at COCP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Cocrystal Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about COCP

What is the COCP stock price forecast for 2026-2027?

The median 12-month analyst price target for Cocrystal Pharma, Inc. is $8, with estimates ranging from $6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COCP stock a buy right now?

Of the 2 analysts covering Cocrystal Pharma, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cocrystal Pharma, Inc. 48 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COCP?

As at 21 Nov 2026, Cocrystal Pharma, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).

Will COCP stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $8, and Ticker Nerd's factor model ranks Cocrystal Pharma, Inc. 48 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COCP stock forecast for 2030?

No analyst covering Cocrystal Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COCP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $10 over the next 12 months.

How has COCP stock performed over the past year?

Cocrystal Pharma, Inc. returned +1.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cocrystal Pharma, Inc. do?

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious viral diseases. The company’s current programs target the replication mechanisms of norovirus, influenza, coronaviruses, and hepatitis C, with an emphasis on oral direct-acting candidates designed for treatment and prevention settings.

Company

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious viral diseases. The company’s current programs target the replication mechanisms of norovirus, influenza, coronaviruses, and hepatitis C, with an emphasis on oral direct-acting candidates designed for treatment and prevention settings. Its pipeline includes drug development efforts that span discovery, preclinical work, and clinical-stage studies, supported by structure-based technologies aimed at identifying differentiated antiviral compounds. Cocrystal Pharma also engages in research partnerships and funding activities that help advance its antiviral portfolio and related scientific programs. Headquartered in Bothell, Washington, Cocrystal Pharma plays a specialized role in the biotechnology market by addressing unmet needs in infectious disease therapeutics through targeted antiviral innovation.

CEO Dr. Sam Lee Ph.D. · 10 employees · United States · https://www.cocrystalpharma.com